

Biocatalysis

International Edition: DOI: 10.1002/anie.201606242
German Edition: DOI: 10.1002/ange.201606242

A Panel of TrpB Biocatalysts Derived from Tryptophan Synthase through the Transfer of Mutations that Mimic Allosteric Activation

Javier Murciano-Calles⁺, David K. Romney⁺, Sabine Brinkmann-Chen, Andrew R. Buller, and Frances H. Arnold*

Abstract: Naturally occurring enzyme homologues often display highly divergent activity with non-natural substrates. Exploiting this diversity with enzymes engineered for new or altered function, however, is laborious because the engineering must be replicated for each homologue. A small set of mutations of the tryptophan synthase β -subunit (TrpB) from *Pyrococcus furiosus*, which mimics the activation afforded by binding of the α -subunit, was demonstrated to have a similar activating effect in different TrpB homologues with as little as 57% sequence identity. Kinetic and spectroscopic analyses indicate that the mutations function through the same mechanism: mimicry of α -subunit binding. From these enzymes, we identified a new TrpB catalyst that displays a remarkably broad activity profile in the synthesis of 5-substituted tryptophans. This demonstrates that allosteric activation can be recapitulated throughout a protein family to explore natural sequence diversity for desirable biocatalytic transformations.

Tryptophan synthases (TrpSs) are $\alpha_2\beta_2$ heterodimer complexes that catalyze the synthesis of tryptophan (**1**) from 3-indole-D-glycerol phosphate (IGP, **2**) and L-serine (**3**, Figure 1a). TrpS also reacts with myriad indole analogues, thereby providing a direct biocatalytic route to tryptophan derivatives.^[1] In such reactions, only the β -subunit (TrpB) performs catalysis (Figure 1b), but its activity is greatly diminished in the absence of the α -subunit (TrpA), which limits its utility as a biocatalyst.^[2] Recently, we applied directed evolution to the β -subunit from *Pyrococcus furiosus* (*Pf*TrpB) to identify mutations that emulate the effect of TrpA binding and imbue the β -subunit with high activity in isolation.^[3] However, this stand-alone catalyst, *Pf*TrpB^{OB2}, exhibited poor levels of activity in the synthesis of 5-substituted tryptophans, a prevalent structural motif in bioactive natural products.^[4] We hypothesized that if TrpB homologues could be activated by transferring the allosteric-mimicking mutations identified in *Pf*TrpB^{OB2}, some of the resultant catalysts might have greater activity with 5-substituted indoles.

The central challenge in enzyme engineering is to traverse the sequence space that separates a wild-type enzyme from its




Figure 1. The native reaction mediated by TrpS, and the catalytic cycle of TrpB. a) TrpA degrades **2** through retro-aldol cleavage to give indole (**4**) and D-glyceraldehyde (**5**). Substrate **4** then reacts with **3** to form **1**. b) TrpB contains a pyridoxal 5'-phosphate (PLP) cofactor bound as an internal aldimine [E(Ain)], which covalently binds **3** as an external aldimine [E(Aex₁)]. Subsequent deprotonation and dehydration form the aminoacrylate E(A-A). Finally, **4** reacts with E(A-A) to form **1**.

variant with novel functional properties. Instead of repeating the directed evolution to activate each new TrpB homologue, we decided to try to shortcut that effort by transferring beneficial mutations discovered in *Pf*TrpB to different homologues. This would create a panel of TrpB enzymes, possibly with different substrate scopes or other useful properties for biocatalytic applications. The transfer of beneficial mutations to other, closely-related enzymes is widely used to improve properties, such as stability, but this approach assumes either that the effects of the mutations are independent and additive, as with thermostabilization by consensus design,^[5] or at least that the protein context is shared (high sequence identity in the region of the mutation).^[6] In an allosterically modulated enzyme such as TrpS, catalytic activity is increased by ligand (TrpA) binding at a location separate from the active site. Allosteric activation

[*] Dr. J. Murciano-Calles,^[†] Dr. D. K. Romney,^[†] Dr. S. Brinkmann-Chen, Dr. A. R. Buller, Prof. Dr. F. H. Arnold
Division of Chemistry and Chemical Engineering
California Institute of Technology, Pasadena, CA 91125 (USA)
E-mail: frances@cheme.caltech.edu

[†] These authors contributed equally to this work.

Supporting information for this article can be found under:
<http://dx.doi.org/10.1002/anie.201606242>.

thus involves the participation of many residues, even the entire protein, as well as the surrounding solvent.^[7] Furthermore, residues that contribute to allosteric signaling are poorly conserved by evolution,^[8] causing homologous proteins to develop different allosteric mechanisms.^[9] It was thus uncertain whether mutations that mimic allostery in TrpS from one species would be generalizable to other homologues.

We selected three phylogenetically diverse TrpB enzymes^[10] to serve as the basis for new stand-alone catalysts: the hyperthermostable enzymes from *Archaeoglobus fulgidus* (AfTrpB, 72 % sequence identity to PfTrpB) and *Thermotoga maritima* (TmTrpB, 64 % identity), and the mesophilic enzyme from *Escherichia coli* (EcTrpB, 57 % identity).^[11] We were especially interested in TmTrpB because its wild-type k_{cat} is already four times that of PfTrpB.^[12] Activation of EcTrpB would be desirable because it is adapted to a different temperature (37 °C versus 96 °C for PfTrpB), which may be useful for less-stable substrates.

Previously, we observed that PfTrpB was a sluggish catalyst (Table 1, entry 1), but that variant PfTrpB^{OB2}, which was engineered using three rounds of directed evolution,

Table 1: Kinetic parameters of the *Pyrococcus furiosus* and *Archaeoglobus fulgidus* TrpB wild-type enzymes and OB2 variants.^[a]

| Entry | Enzyme | k_{cat} [s ⁻¹] | K_{M} [μM indole] | $k_{\text{cat}}/K_{\text{M}}$ [μM ⁻¹ s ⁻¹ indole] |
|------------------|-----------------------|--|-------------------------------|--|
| 1 | PfTrpB ^{WT} | 0.31 | 77 | 4.0 |
| 2 ^[b] | PfTrpB ^{OB2} | 2.9 | 9 | 300 |
| 3 | AfTrpB ^{WT} | 0.074 | 12 | 6.0 |
| 4 ^[c] | AfTrpB ^{OB2} | 0.51 | 4.8 | 110 |

[a] Assays conducted in potassium phosphate buffer (pH 8) at 75 °C for Pf and 60 °C for AfTrpB. See Section 5.4 in the Supporting Information for experimental details. Standard errors are shown in Table S1. [b] Contains the mutations P12L, E17G, I68V, F274S, T292S, and T321A. [c] Contains the mutations P25L, P30G, I80V, L285S, T303S, and T321A.

exhibited a 9-fold increase in k_{cat} with an equivalent decrease in K_{M} (Table 1, entry 2). We expressed and purified the three TrpB homologues and their corresponding OB2 variants to test whether the activating mutations would produce a similar effect. Compared to AfTrpB (Table 1, entry 3), the variant AfTrpB^{OB2} has a 7-fold higher k_{cat} and 2-fold lower K_{M} for indole (Table 1, entry 4).

The absorption spectrum of PLP changes as the cofactor passes through different stages of the catalytic cycle (Figure 1b).^[2a] The absorption spectrum of the enzyme under reaction conditions thus directly reflects the steady-state distribution of catalytic intermediates. Before the addition of Ser, AfTrpS, AfTrpB, and AfTrpB^{OB2} all display an absorbance peak at 412 nm (Figure 2), which corresponds to the absorbance of E(A_{in}). When Ser is added to AfTrpS, its spectrum exhibits a new λ_{max} at 350 nm (Figure 2a), thus indicating that E(A-A) is prevalent in the steady state of the catalytic cycle for this enzyme. Conversely, AfTrpB lacks a λ_{max} at 350 nm, but instead shows an absorbance peak at 428 nm (Figure 2b), thus indicating that E(Aex₁) is the most prevalent intermediate. The spectrum of AfTrpB^{OB2}, on the other hand, is almost




Figure 2: UV/Vis absorption spectra of AfTrpS (a), AfTrpB (b), and AfTrpB^{OB2} (c) before (solid black line) and after (dashed gray line) addition of L-serine.

identical to that of AfTrpS, with a prominent λ_{max} of 350 nm (Figure 2c). This behavior matches what we observed previously^[3] and provides compelling evidence that the OB2 mutations activate AfTrpB by the same mechanism as they did in PfTrpB, namely by mimicking the allosteric activation produced by the binding of TrpA to TrpB.

The TmTrpB homologue (Table 2, entry 1) already contains the residue A321 in its native sequence. However, incorporation of the remaining five mutations from PfTrpB^{OB2} reduced the k_{cat} to just 10 % of the wild-type activity (Table 2, entry 2). To investigate whether a subset of these mutations could still be activating, we constructed a recombination library of the OB2 mutations in TmTrpB and screened for activity with indole. Three mutations, P19G, I69V, and T292S, increased the activity with respect to the wild-type enzyme.

Table 2: Kinetic parameters of *Thermotoga maritima* TrpB variants and TrpS.^[a]

| Entry | Enzyme | k_{cat} [s ⁻¹] | K_{M} [μM indole] | $k_{\text{cat}}/K_{\text{M}}$ [μM ⁻¹ s ⁻¹ indole] |
|-------|------------------------------|--|-------------------------------|--|
| 1 | TmTrpB ^{WT} | 1.28 | 33 | 39 |
| 2 | TmTrpB ^{OB2} [b] | 0.11 | 72 | 2.0 |
| 3 | TmTrpB ^{triple} [c] | 9.8 | 26 | 380 |
| 4 | TmTrpB ^{T292S} | 5.8 | 25 | 230 |
| 5 | TmTrpS | 2.2 | 44 | 50 |

[a] Assays conducted in potassium phosphate buffer (pH 8) at 75 °C. See Section 5.4 in the Supporting Information for experimental details. Standard errors are shown in Table S1. [b] Contains the mutations P14L, P19G, I69V, L274S and T292S. [c] Contains the mutations P19G, I69V, and T292S.

The variant with all three mutations was most active, with an 8-fold increase in k_{cat} (Table 2, entry 3). The T292S mutation by itself was also substantially activating, producing a 4-fold increase in k_{cat} (Table 2, entry 4).

As with *Af*TrpS and *Pf*TrpS, the UV/Vis absorption spectrum of *Tm*TrpS exhibits a strong λ_{max} at 350 nm under the reaction conditions. Once again, *Tm*TrpB lacks this probative peak and instead exhibits the λ_{max} at 428 nm that was observed for *Af*TrpB and *Pf*TrpB. While all permutations of the three mutations (P19G, I69V, and T292S) led to improved k_{cat} values (Figure S3), only the variants with T292S exhibited a λ_{max} at 350 nm, like *Tm*TrpS (Figure S4). The importance of the T292S mutation was also observed in *Pf*TrpB, where this mutation alone restored the k_{cat} of the isolated *Pf*TrpB to that of the *Pf*TrpS complex.^[3] The effects of this conservative mutation were even more dramatic in *Tm*TrpB, producing a k_{cat} almost 3-fold higher than that of *Tm*TrpS (Table 2, cf. entries 4 and 5).

Mutational activation of the most distant homologue, *Ec*TrpB (57% identity), proved more challenging. The crucial Thr→Ser mutation was not possible for *Ec*TrpB because *Ec*TrpB already has Ser at this position (S297). Site-saturation mutagenesis confirmed that serine is the optimal residue at that position (Figure S5a). Unlike *Tm*TrpB, recombination of the 0B2 mutations in *Ec*TrpB yielded no variants with enhanced activity and only a few with activity similar to the wild-type enzyme (Figure S5b).

The initial screening effort with *Pf*TrpB^[3] had also identified a variant with the mutations M144T and N166D that was almost as active as *Pf*TrpB^{T292S} (Table 3, entry 1).

Table 3: Kinetic parameters of *Pyrococcus furiosus* TrpB^{M144T N166D} and its homologues.^[a]

| Entry | Enzyme | k_{cat} [s ⁻¹] | K_{M} [μM indole] | $k_{\text{cat}}/K_{\text{M}}$ [μM ⁻¹ s ⁻¹ indole] |
|------------------|---------------------------------------|--|-------------------------------|--|
| 1 | <i>Pf</i> TrpB ^{M144T N166D} | 0.83 | 42 | 20 |
| 2 ^[b] | <i>Ec</i> TrpB ^{M149T N171D} | 0.34 | 18 | 19 |
| 3 | <i>Tm</i> TrpB ^{M145T N167D} | 3.3 | 32 | 100 |
| 4 | <i>Af</i> TrpB ^{M156T N178D} | 0.34 | 11 | 31 |

[a] Assays conducted in potassium phosphate buffer (pH 8) at 75 °C for *Pf* and *Tm*, 60 °C for *Af*, and 37 °C for *Ec*TrpB. See Section 5.4 in the Supporting Information for experimental details. Standard errors are shown in Table S1. [b] *Ec*TrpB has the following characteristics: $k_{\text{cat}}=0.16 \text{ s}^{-1}$; $K_{\text{M}}=19 \text{ μM}$ (indole); $k_{\text{cat}}/K_{\text{M}}=8 \text{ μM}^{-1} \text{ s}^{-1}$ (indole).

These two residues, unlike T292, reside in the so-called communication (COMM)^[2a] domain, which interfaces with TrpA and undergoes large conformational motions during the catalytic cycle. These residues are identical in the four homologues studied here and are almost universally conserved across all TrpBs (Figure S6). We hypothesized that the effects of mutations at these sites might also be transferrable. Upon making the equivalent mutations in *Ec*TrpB, *Tm*TrpB, and *Af*TrpB, we observed activation in all variants, with approximately 2- to 5-fold increases in k_{cat} (Table 3, entries 2–4).

We wished to verify that the proteins were still being activated by allosteric mimicry. UV/Vis analysis of the steady-

state distributions of intermediates upon addition of L-serine revealed that the double mutants of *Pf*TrpB and *Ec*TrpB still accumulated E(Aex_i) rather than E(A-A) (Figure S7a,d). However, the homologous double mutants of the *A. fulgidus* and *T. maritima* enzymes showed shifted spectra in which E(A-A) predominated (Figure S7b,c). These data suggest that the double mutation also activates the enzymes through allosteric mimicry, but that it does not quite reach the activation generated by adding TrpA. This situation is reminiscent of the earlier evolution of *Pf*Trp^{0B2}, wherein the lone T292S mutation was insufficient to completely shift the UV/Vis spectrum to E(A-A) without at least four additional mutations.^[3]

In the pantheon of tryptophan-derived natural products, one can find substitution at every position on the indole moiety (Figure 3). Position 5, for example, is chlorinated by





Figure 3. Numbering of the positions on the indole moiety of tryptophan, and examples of natural products bearing substitutions at position 5.

the halogenase PyrH en route to pyroindomycin B (**6**),^[4a] and mono-oxygenated by tryptophan hydroxylase in the biosynthesis of serotonin (**7**) and melatonin (**8**).^[4d] Such substituents have a profound effect on biological activity because they can mask sites of metabolic degradation and change the electronic properties of the compound. This, in turn, alters properties like solubility and creates new binding interactions through effects such as π stacking and halogen bonding.^[1b,13] Halogens can also provide handles for further diversification of biologically active compounds through cross-coupling reactions.^[14] While chemical and biosynthetic routes to tryptophan derivatives tend to be inefficient, TrpS can provide direct access to many of these products. Previously, however, 5-substituted indoles bearing any substituents larger than fluorine caused a substantial decrease in activity.^[1d,f,15] Furthermore, TrpS activity with electron-deficient indoles has not been explored.

One enzyme in our repertoire, *Tm*TrpB^{M145T N167D}, showed higher activity with 5-bromoindole than even our most optimized catalyst, *Pf*TrpB^{0B2} (Figure S8). To assess whether this was a general property of the catalyst, we compared the relative rates of *Tm*TrpB^{M145T N167D} and *Pf*TrpB^{0B2} with a set of challenging 5-substituted indoles (Table 4). We then applied *Tm*TrpB^{M145T N167D} in reactions that were run to higher conversion in order to isolate and characterize the products.

With 5-chloroindole, the *Tm* variant exhibits a 3-fold rate enhancement compared to *Pf*TrpB^{0B2} (Table 4, entry 1). Despite this improvement, the reaction still appeared to stall at about 85% conversion when the substrates were used in equal amounts, possibly due to competing decomposition

Table 4: Synthesis of 5-substituted tryptophan derivatives with *Thermotoga maritima* TrpB^{M145T N167D} [a]


| Entry | X | Relative rate vs. <i>PfTrpB</i> ^{OB2} | Yield [%] ^[b] | Total turnovers ^[c] |
|-------|--------------------|--|--------------------------|--------------------------------|
| 1 | Cl | 3.0 | 93 | 9300 |
| 2 | Br | 5.6 | 88 | 4400 |
| 3 | NO ₂ | 7.5 | 25 | 1250 |
| 4 | CN | 4.5 | 49 | 2450 |
| 5 | CHO | 1.9 | 32 | 1600 |
| 6 | B(OH) ₂ | 1.8 | 38 ^[d] | 1900 ^[d] |
| 7 | OH | 1.4 | 93 ^[d] | 9300 ^[d] |
| 8 | CH ₃ | 1.4 | 91 | 9100 |
| 9 | OCH ₃ | 1.5 | 76 | 7600 |

[a] See Section 6 in the Supporting Information for experimental details. Standard errors are in Table S2. [b] Reactions used either 2 equiv (entries 1–6) or 1.2 equiv (entries 7–9) of L-serine. Products were isolated by chromatography with C-18 silica and the yield of isolated product is shown. [c] Extrapolated from the yield of isolated product based on maximum theoretical turnover number. [d] Determined by ¹H NMR based on an internal standard.

of serine.^[16] We overcame this limitation by using a small excess of serine, which led to the isolation of 5-chlorotryptophan in 94 % yield. *PfTrpB*^{OB2} has even greater difficulty with 5-bromoindole, but the *Tm* variant is almost six times as fast for this substrate, leading to 5-bromotryptophan in 88 % yield of isolated product (Table 4, entry 2). These results compare favorably with previous reports, in which TrpS from *Salmonella enterica* was shown to form 5-chloro and 5-bromotryptophan in 61 % and 26 % yield, respectively.^[17] *TmTrpB*^{M145T N167D} exhibits substantially faster rates, ranging from 2- to over 7-fold, with substrates that bear electron-withdrawing groups, such as nitro, cyano, formyl, and even boronate (Table 4, entries 3–6), which represents a new substrate class in the TrpS literature. The reaction with 5-boronoindole is particularly interesting since the catalyst must contend with competing proto-deborylation. Boronic acids can serve as handles for bioorthogonal conjugation,^[17] pH-sensitive delivery of therapeutics in vivo,^[18] and substrates for cross-coupling, thereby complementing 5-halotryptophans, for which electron-deficient coupling partners lead to reduced yields.^[19] Although the reactivity with these new substrates remains low, we believe that *TmTrpB*^{M145T N167D}, which only has two mutations compared to six in *PfTrpB*^{OB2}, is the ideal parent for further optimization.

PfTrpB^{OB2} already shows excellent activity with substrates that bear electron-donating groups at the 5-position (e.g., hydroxy, methyl, and methoxy groups); nonetheless, *TmTrpB*^{M145T N167D} delivers a 1.5-fold faster rate (Table 4, entries 7–9), which is helpful because such electron-rich substrates are prone to aerobic oxidation. *TmTrpB*^{M145T N167D} performs almost 10,000 turnovers in just two hours, which

allows the products to be isolated in high yield without the need for oxygen-free conditions.

By mining the wealth of activating mutations in *PfTrpB*, we have identified subsets that retain their effects when transferred into related enzymes, including those from different domains of life (Archaea and Bacteria). Importantly, spectroscopic data indicate that the homologues are activated through the same mechanism as the *PfTrpB* variants, namely mimicking the effects of TrpA binding. By screening the resulting panel of activated TrpB homologues, we have identified a variant with broadly improved activity toward 5-substituted indoles, a substrate class that had proven problematic for all previous catalysts. The strategy used here could be applied to other TrpBs and exemplifies how the transfer of activating mutations to homologous enzymes can rapidly expand activity with non-native substrates.

Acknowledgements

The authors thank Dr. Jackson Cahn for the data on frequency of amino acids in each position of TrpB and Dr. Jennifer Kan for helpful discussions and comments on the manuscript. J.M.-C. gratefully acknowledges support from the Alfonso Martín Escudero Foundation. This work was funded through the Jacobs Institute for Molecular Engineering for Medicine and Ruth Kirschstein NIH Postdoctoral Fellowships F32GM117635 (to D.K.R.) and F32GM110851 (to A.R.B.).

Keywords: allostery · enzymes · protein engineering · tryptophan synthase

How to cite: *Angew. Chem. Int. Ed.* **2016**, 55, 11577–11581
Angew. Chem. **2016**, 128, 11749–11753

- [1] a) D. Ferrari, L. H. Yang, E. W. Miles, M. F. Dunn, *Biochemistry* **2001**, 40, 7421–7432; b) R. J. M. Goss, P. L. A. Newill, *Chem. Commun.* **2006**, 4924–4025; c) M. Winn, A. D. Roy, S. Grünschow, R. S. Parameswaran, R. J. M. Goss, *Bioorg. Med. Chem. Lett.* **2008**, 18, 4508–4510; d) A. N. Tsoligkas, M. Winn, J. Bowen, T. W. Overton, M. J. H. Simmons, R. J. M. Goss, *ChemBioChem* **2011**, 12, 1391–1395; e) S. Perni, L. Hackett, R. J. Goss, M. J. Simmons, T. W. Overton, *AMB Express* **2013**, 3, 66–75; f) D. R. M. Smith, T. Willemse, D. S. Gkotsi, W. Schepens, B. U. W. Maes, S. Ballet, R. J. M. Goss, *Org. Lett.* **2014**, 16, 2622–2625; g) M. J. Corr, D. R. M. Smith, R. J. M. Goss, *Tetrahedron* **2016**, DOI: 10.1016/j.tet.2016.02.016.
- [2] a) M. F. Dunn, *Arch. Biochem. Biophys.* **2012**, 519, 154–166; b) D. Niks, E. Hilario, A. Dierkers, H. Ngo, D. Borchardt, T. J. Neubauer, L. Fan, L. J. Mueller, M. F. Dunn, *Biochemistry* **2013**, 52, 6396–6411.
- [3] A. R. Buller, S. Brinkmann-Chen, D. K. Romney, M. Herger, J. Murciano-Calles, F. H. Arnold, *Proc. Natl. Acad. Sci. USA* **2015**, 112, 14599–14604.
- [4] a) S. Zehner, A. Kotzsch, B. Bister, R. D. Süßmuth, C. Méndez, J. A. Salas, K.-H. van Pée, *Chem. Biol.* **2005**, 12, 445–452; b) P. Zhang, X. Sun, B. Xu, K. Bijian, S. Wan, G. Li, M. Alaoui-Jamali, T. Jiang, *Eur. J. Med. Chem.* **2011**, 46, 6089–6097; c) H. Wang, S. E. Reisman, *Angew. Chem. Int. Ed.* **2014**, 53, 6206–6210; *Angew. Chem.* **2014**, 126, 6320–6324; d) J. Zhang, C. Wu, J. Sheng, X. Feng, *Mol. Biosyst.* **2016**, 12, 1432–1435.

- [5] M. Lehmann, M. Wyss, *Curr. Opin. Biotechnol.* **2001**, *12*, 371–375.
- [6] a) S. Brinkmann-Chen, T. Flock, J. K. B. Cahn, C. D. Snow, E. M. Brustad, J. A. McIntosh, P. Meinhold, L. Zhang, F. H. Arnold, *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 10946–10951; b) T. Heel, J. A. McIntosh, S. C. Dodani, J. T. Meyerowitz, F. H. Arnold, *ChemBioChem* **2014**, *15*, 2556–2562; c) A. Khanal, S. Yu McLaughlin, J. P. Kershner, S. D. Copley, *Mol. Biol. Evol.* **2015**, *32*, 100–108; d) M. R. Dunn, C. Otto, K. E. Fenton, J. C. Chaput, *ACS Chem. Biol.* **2016**, *11*, 1210–1219.
- [7] N. V. Dokholyan, *Chem. Rev.* **2016**, *116*, 6463–6487.
- [8] R. Nussinov, C.-J. Tsai, P. Csermely, *Trends Pharmacol. Sci.* **2011**, *32*, 686–693.
- [9] J. Kuriyan, D. Eisenberg, *Nature* **2007**, *450*, 983–990.
- [10] R. Merkl, *BMC Evol. Biol.* **2007**, *7*, 59.
- [11] For sequence and structure alignments, see the Supporting Information.
- [12] S. Hettwer, R. Sterner, *J. Biol. Chem.* **2002**, *277*, 8194–8201.
- [13] C. S. Neumann, D. G. Fujimori, C. T. Walsh, *Chem. Biol.* **2008**, *15*, 99–109.
- [14] a) A. D. Roy, S. Grüşchow, N. Cairns, R. J. M. Goss, *J. Am. Chem. Soc.* **2010**, *132*, 12243–12245; b) T. P. Pathak, S. J. Miller, *J. Am. Chem. Soc.* **2013**, *135*, 8415–8422; c) L. J. Durak, J. T. Payne, J. C. Lewis, *ACS Catal.* **2016**, *6*, 1451–1454.
- [15] G. Blaser, J. M. Sanderson, A. S. Batsanov, J. Howard, *Tetrahedron Lett.* **2008**, *49*, 2795–2798.
- [16] I. P. Crawford, J. Ito, *Proc. Natl. Acad. Sci. USA* **1964**, *51*, 390–397.
- [17] B. Akgun, D. G. Hall, *Angew. Chem. Int. Ed.* **2016**, *55*, 3909–3913; *Angew. Chem.* **2016**, *128*, 3977–3981.
- [18] a) H. Han, M. E. Davis, *Bioconjugate Chem.* **2013**, *24*, 669–677; b) D. W. Pan, M. E. Davis, *Bioconjugate Chem.* **2015**, *26*, 1791–1803.
- [19] A. D. Roy, R. J. M. Goss, G. K. Wagner, M. Winn, *Chem. Commun.* **2008**, 4831–4833.

Received: June 27, 2016

Published online: August 11, 2016